168 related articles for article (PubMed ID: 29078273)
1. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.
Nakamura M; Zhang Y; Yang Y; Sonmez C; Zheng W; Huang G; Seki T; Iwamoto H; Ding B; Yin L; Foukakis T; Hatschek T; Li X; Hosaka K; Li J; Yu G; Wang X; Liu Y; Cao Y
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9635-E9644. PubMed ID: 29078273
[TBL] [Abstract][Full Text] [Related]
2. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
4. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic Therapy in Colorectal Cancer.
Mody K; Baldeo C; Bekaii-Saab T
Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.
Tankiewicz-Kwedlo A; Hermanowicz J; Surażynski A; Rożkiewicz D; Pryczynicz A; Domaniewski T; Pawlak K; Kemona A; Pawlak D
Mol Cell Biochem; 2016 Oct; 421(1-2):1-18. PubMed ID: 27543111
[TBL] [Abstract][Full Text] [Related]
7. miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers.
Amerizadeh F; Khazaei M; Maftouh M; Mardani R; Bahrami A
Curr Pharm Des; 2018; 24(39):4668-4674. PubMed ID: 30636586
[TBL] [Abstract][Full Text] [Related]
8. Endogenous erythropoietin and erythropoietin receptors in colorectal cancer; can we answer the questions?
Čubranić A; Dobrila-Dintinjana R; Redžović A; Dintinjana M; Petranović D; Golčić M
Med Hypotheses; 2016 Nov; 96():16-19. PubMed ID: 27959268
[TBL] [Abstract][Full Text] [Related]
9. Mystery Story about Erythropoietin (Epo) and Erythropoietin Receptor (EpoR) are Disguised?
Cubranić A; Redzovic A; Dobrila-Dintinjana R; Vukelić J; Dintinjana M
Hepatogastroenterology; 2015 May; 62(139):585-9. PubMed ID: 26897933
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
13. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer.
Li G; Zheng J; Xu B; Ling J; Qiu W; Wang Y
Biomed Pharmacother; 2017 Jan; 85():418-424. PubMed ID: 27887848
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.
Ribatti D; Poliani PL; Longo V; Mangieri D; Nico B; Vacca A
Histopathology; 2007 Apr; 50(5):636-41. PubMed ID: 17394500
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma.
Ribatti D; Marzullo A; Gentile A; Longo V; Nico B; Vacca A; Dammacco F
Histopathology; 2007 Apr; 50(5):591-6. PubMed ID: 17394495
[TBL] [Abstract][Full Text] [Related]
20. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
